A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Recruiting now · Phase 1
Conditions studied: Recurrent or Metastatic Solid Tumors
In brief
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.
Key facts
- Study ID
- NCT07015697
- Run by
- Daiichi Sankyo
- People needed
- 76
- Starts
- 2025-07-17
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Taoyuan City, Taiwan (enrolling)
- Research Site — Atlanta, Georgia, United States (enrolling)
- Research Site — Las Vegas, Nevada, United States (enrolling)
- Research Site — Charlotte, North Carolina, United States (enrolling)
- Research Site — Maumee, Ohio, United States (enrolling)
- Research Site — Nashville, Tennessee, United States (enrolling)
- Research Site — Taichung, Taiwan (enrolling)
- Research Site — Tainan, Taiwan (enrolling)
- Research Site — Taipei, Taiwan (enrolling)
- Research Site — Taipei, Taiwan (enrolling)
- Research Site — Newport Beach, California, United States (enrolling)
- Research Site Saint — Herblain, France (enrolling)
- Research Site — Rennes, France (enrolling)
- Research Site — Chiba, Japan (enrolling)
- Research Site — Kanagawa, Japan (enrolling)
- Research Site — Tokyo, Japan (enrolling)
- Research Site — Tokyo, Japan (enrolling)
- Research Site — Tokyo, Japan (enrolling)
- Research Site — Seongnam-si, South Korea (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Barcelona, Spain (enrolling)
- Research Site — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.